From: Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts
 | Patients N = 318 (%) |
---|---|
Age (years) | |
 Median (range) | 68.6 (32–90) |
Gender | |
 M | 223 (70.13) |
 F | 95 (29.87) |
Histology | |
 NSCLC | 200 (62.89) |
 Melanoma | 87 (27.36) |
 Kidney | 23 (7.23) |
 Others | 8 (2.52) |
ECOG PS | |
 0 | 199 (62.58) |
 1 | 102 (32.07) |
 ≥ 2 | 17 (5.35) |
Number of metastatic sites | |
 < 3 | 214 (67.3) |
 ≥ 3 | 104 (32.7) |
Metastasis | |
 CNS | 40 (12.58) |
 Bone | 60 (18.87) |
 Liver | 28 (8.81) |
Previous lines of treatments | |
 0 | 122 (38.37) |
 1 | 126 (39.62) |
 ≥ 2 | 70 (22.01) |
Immunotherapeutic agents | |
 Pembrolizumab | 126 (39.62) |
 Nivolumab | 187 (58.81) |
 Atezolizumab | 5 (1.57) |
Duration of Immunotherapy | |
 ≥ 12 months < 18 | 121 (38.05) |
 ≥ 18 months < 24 | 94 (29.56) |
 ≥ 24 months < 36 | 80 (25.16) |
 ≥ 36 months | 23 (7.23) |
Best response | |
 SD | 88 (27.67) |
 PR | 197 (61.95) |
 CR | 33 (10.38) |